Alginate/chitosan nanoparticles are effective for oral insulin delivery

Pharmaceutical Research

Volumn 24, Issue 12, 2007, Pages 2198-2206

  Sarmento, B ^a   Ribeiro, A ^b   Veiga, F ^b   Sampaio, P ^c   Neufeld, R ^d   Ferreira, D ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Hypoglycemic effect; Insulin; Nanoparticle; Natural polymers; Oral delivery

Indexed keywords

ALGINIC ACID; CHITOSAN; FLUORESCEIN ISOTHIOCYANATE; GLUCOSE; INSULIN; NANOPARTICLE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GASTROINTESTINAL TRACT; GELATION; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; IN VIVO STUDY; INTESTINE EPITHELIUM; INTESTINE MUCOSA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ALGINATES; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; FLUORESCEIN-5-ISOTHIOCYANATE; GLUCURONIC ACID; HEXURONIC ACIDS; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; INSULIN; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; MICROSCOPY, CONFOCAL; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SOLUBILITY;

EID: 35848959714     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9367-4     Document Type: Article

References (54)

1. F. Delie and M. J. Blanco-Prieto. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10:65-80 (2005).
2. A. des Rieux, V. Fievez, M. Garinot, Y.-J. Schneider, and V. Preat. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Release 116:1-27 (2006).
3. S. A. Galindo-Rodriguez, E. Allémann, H. Fassi, and E. Doelker. Polymeric nanoparticles for oral delivery of drugs and vacines: A critical evaluation of in vivo studies. Crit. Rev. Ther. Drug 22:419-463 (2005).
4. A. Florence. The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual. Pharm. Res. 14:259-266 (1997).
5. M. Morishita and N. A. Peppas. Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11:905-910 (2006).
6. M. Bendayan, E. Ziv, D. Gingras, R. Ben-Sasson, H. Bar-On, and M. Kidron. Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 37:119-126 (1994).
7. E. Ziv and M. Bendayan. Intestinal absorption of peptides through the enterocytes. Microsc. Res. Tech. 49:346-352 (2000).
8. A. Fasano. Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol. 16:152-157 (1998).
9. H. Pinto-Alphandary, M. Aboubakar, D. Jaillard, P. Couvreur, and C. Vauthier. Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm. Res. 20:1071-1084 (2003).
10. O. Borges, A. Cordeiro-da-Silva, S. G. Romeijn, M. Amidi, A. de Sousa, G. Borchard, and H. E. Junginger. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J. Control. Release 114:348-358 (2006).
11. N. Hussain, V. Jaitley, and A. T. Florence. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50:107-142 (2001).
12. M. G. Qaddoumi, H. J. Gukasyan, J. Davda, V. Labhasetwar, K. J. Kim, and V. H. Lee. Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol. Vis. 9:559-568 (2003).
13. T. Jung, W. Kamm, A. Breitenbach, E. Kaiserling, J. X. Xiao, and T. Kissel. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50:147-160 (2000).
14. H. S. Yoo and T. G. Park. Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J. Pharm. Sci. 93:488-495 (2004).
15. W. Tiyaboonchai, J. Woiszwillo, R. C. Sims, and C. R. Middaugh. Insulin containing polyethylenimine-dextran sulfate nanoparticles. Int. J. Pharm. 255:139-151 (2003).
16. W. R. Gombotz and S. F. Wee. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31:267-285 (1998).
17. L. Ilium. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15:1326-1331 (1998).
18. L. Illum, N. F. Farraj, and S. S. Davis. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11:1186-1189 (1994).
19. P. Artursson. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1358-1361 (1994).
20. M. Prabaharan and J. F. Mano. Chitosan-based particles as controlled drug delivery systems. Drug Deliv. 12:41-57 (2005).
21. B. Sarmento, A. J. Ribeiro, F. Veiga, D. C. Ferreira, and R. J. Neufeld. Insulin-loaded nanoparticles are prepared by alginate ionotropic pre-gelation followed by chitosan polyelectrolyte complexation. J. Nanosci. Nanotechnol. 7:2833-2841 (2007).
22. M. van de Weert, W. E. Hennink, and W. Jiskoot. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17:1159-1167 (2000).
23. C. Damge, H. Vrancks, P. Balschmidt, and P. Couvreur. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86:1407-1500 (1997).
24. G. P. Carino, J. S. Jacob, and E. Mathiowitz. Nanosphere based oral insulin delivery. J. Control. Release 65:261-269 (2000).
25. X. Y. Ma, G. M. Pan, Z. Lu, J. S. Hu, J. Z. Bei, J. H. Jia, and S. G. Wang. Preliminary study of oral polylactide microcapsulated insulin in vitro and in vivo. Diabetes Obes. Metab. 2:243-250 (2000).
26. B. Sarmento, D. C. Ferreira, L. Jorgensen, and M. van de Weert. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. Eur. J. Pharm. Biopharm. 65:10-17 (2007).
27. T. K. Tugrul. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16:351-380 (1995).
28. X. Cao, S. Gibbs, L. Fang, H. Miller, C. Landowski, H.-C. Shin, H. Lennernas, Y. Zhong, G. Amidon, L. Yu, and D. Sun. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23:1675-1686 (2006).
29. M. M. Lerco, C. T. Spadella, and J. L. M. Machado. Experimental alloxan diabetes-induced: a model for clinical and laboratory studies in rats. Acta Cir. Bras. 18:132-142 (2003).
30. B. Sarmento, A. Ribeiro, F. Veiga, and D. Ferreira. Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. Biomed. Chromatogr. 20:898-903 (2006).
31. G. Coppi, V. Iannuccelli, E. Leo, M. T. Bernabei, and R. Cameroni. Protein immobilization in crosslinked alginate microparticles. J. Microencapsul. 19:37-44 (2002).
32. G. W. Vandenberg and J. De La Noue. Evaluation of protein release from chitosan-alginate microcapsules produced using external or internal gelation. J. Microencapsul. 18:433-441 (2001).
33. Z. Ma, T. M. Lim, and L.-Y. Lim. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int. J. Pharm. 293:271-280 (2005).
34. Y. Pan, Y. J. Li, H. Y. Zhao, J. M. Zheng, H. Xu, G. Wei, J. S. Hao, and F. D. Cui. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249:139-147 (2002).
35. M. Morishita, I. Morishita, K. Takayama, Y. Machida, and T. Nagai. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16:68-72 (1993).
36. N. Gallo-Payet and J. S. Hugon. Insulin receptors in isolated adult mouse intestinal cells: studies in vivo and in organ culture. Endocrinology 114:1885-1892 (1984).
37. A. M. Lowman, M. Morishita, M. Kajita, T. Nagai, and N. A. Peppas. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci. 88:933-937 (1999).
38. Y. H. Lin, F. L. Mi, C. T. Chen, W. C. Chang, S. F. Peng, H. F. Liang, and H. W. Sung. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8:146-152 (2007).
39. Z. Ahmad, R. Pandey, S. Sharma, and G. K. Khuller. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int. J. Antimicrob. Agents 27:409-416 (2006).
40. F. Cui, K. Shi, L. Zhang, A. Tao, and Y. Kawashima. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114:242-250 (2006).
41. J. Kreuter. Colloidal drug delivery systems, M. Dekker, New York, (1994).
42. P. Couvreur, C. Dubernet, and F. Puisieux. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm. 41:2-13 (1995).
43. A. Amin, T. Shah, J. Patel, and A. Gajjar. Current status of non-invasive insulin delivery technologies. Drug Deliv. Technol. 7:48-55 (2007).
44. H. Chen and R. Langer. Oral particulate delivery: status and future trends. Adv. Drug Deliv. Rev. 34:339-350 (1998).
45. A. Buda, C. Sands, and M. A. Jepson. Use of fluorescence imaging to investigate the structure and function of intestinal M cells. Adv. Drug Deliv. Rev. 57:123-134 (2005).
46. C.-M. Lehr, J. A. Bouwstra, E. H. Schacht, and H. E. Junginger. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78:43-48 (1992).
47. K. A. Janes, P. Calvo, and M. J. Alonso. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47:83-97 (2001).
48. L. Illum. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15:1326-1331 (1998).
49. M. George and T. E. Abraham. Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan-a review. J. Control. Release 114:1-14 (2006).
50. M. Thanou, J. C. Verhoef, and H. E. Junginger. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 50:91-101 (2001).
51. N. Salamat-Miller and T. P. Johnston. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm. 294:201-216 (2005).
52. S. Mao, O. Germershaus, D. Fischer, T. Linn, R. Schnepf, and T. Kissel. Uptake and transport of PEG-graft-trimethyl-chitosan copolymers as insulin nanocomplexes by epithelial cells. Pharm. Res. 22:2058-2068 (2005).
53. Z. Ma and L.-Y. Lim. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res. 20:1812-1819 (2003).
54. C. Prego, D. Torres, and M. J. Alonso. The potential of chitosan for the oral administration of peptides. Expert. Opin. Drug Deliv. 2:843-854 (2005).